In the present study, it was disclosed that PLK4 inhibitor suppressed the activation of Wnt/β-catenin pathway in ATC cell lines, which is in accordance with some previous studies on other carcinomas.27–29 Besides, we hypothesize that the combination of PLK4 inhibitor and sorafenib might exhibit a synergistic effect on downregulating Wnt/β-catenin signaling compared with monotherapy. The gene discussed is PLK4; the disease is carcinoma.